Annals of Oncology
78P Prognostic value of thyroid transcription factor-1 expression
in lung adenocarcinoma in patients treated with anti PD-1/
PD-L1
L. Galland1, J. Lecuelle1, A.L. Lepage2, F. Bibeau3, V. Derangere1, C. Truntzer1,
F. Ghiringhelli4
1
Oncology Department, Centre Georges-François Leclerc, Dijon, France; 2Department
of Medical Oncology, Caen University Hospital, Caen, France; 3Service d’Anatomie
Pathologique, CHU de Caen - Hopital Cote de Nacre, Caen, France; 4Medical Oncology,
Centre Georges-François Leclerc, Dijon, France
Background: Anti-PD1/PD-L1-directed immune checkpoint inhibitors (ICI) are game
changers in advanced non-small-cell lung cancer (NSCLC), but biomarkers are lacking.
The aim of our study was to find clinically relevant biomarkers of the efficacy of ICI in
non-squamous NSCLC.
Methods: We conducted a retrospective study of patients receiving ICI for advanced
non squamous NSCLC in two cohorts. For a subset of patients, RNAseq data were
generated on tumor biopsy taken before ICI. The primary end point was progression-
free survival (PFS) under ICI. Secondary end point was overall survival (OS) from ICI
initiation.
Results: In our cohort, we studied 231 patients. Clinical characteristics included KRAS
mutant status (n¼88), TTF1-positive expression (n¼136), LIPI (Lung Immune Prog-
nostic Index) score of 0 (n¼116). In the training set, by multivariate Cox analysis, lack
of TTF1 expression, LIPI score>0, line of treatment>1, and presence of liver me-
tastases were associated with poorer PFS, while WHO performance status, lack of
TTF1 expression, LIPI score>0, line of treatment>1, and presence of liver or bone
metastases were associated with poorer OS. TTF1 and PD-L1 status could be used to
stratify PFS and OS and improve the AUC for prediction of prognosis in comparison
with the PD-L1 gold standard. Using an external validation cohort of 154 patients
treated with ICI for non-squamous NSCLC, we confirmed the independent prognostic
role of TTF1. Similarly, use of TTF1 with PD-L1 status could be used to stratify PFS and
OS and improve the AUC for the prediction of prognosis in comparison to the PD-L1
gold standard.
Conclusions: TTF1 expression and PD-L1 can be used to stratify risk and predict PFS
and OS in patients treated with ICI for NS-NSCLC.
Legal entity responsible for the study: Centre Georges-François Leclerc.
Funding: Has not received any funding.
Disclosure: All authors have declared no conflicts of interest.
https://doi.org/10.1016/j.annonc.2021.08.358
79P SETD2 a potential tissue-agnostic predictive biomarker for
ICIs in solid tumors
Y. Chen1, X. Zheng2, J. Xiong1, Y. Guan3, Y. Li2, X. Gao3, J. Lin1, Z. Fei4, L. Chen1,
L. Chen1, G. Chen5, X. Yi3, W. Cao6, X. Ai7, C. Zhou8, X. Li9, J. Zhao10, X. Yan11, Q. Yu12,
C. Chen13
1
Department of Medical Oncology, Fujian Medical University Cancer Hospital & Fujian
Cancer Hospital, Cancer Bio-Immunotherapy Center, Fujian Medical University Cancer
Hospital & Fujian Cancer Hospital, Fuzhou, China; 2Fujian Medical University, Cancer
Hospital, Fuzhou, China; 3Geneplus-Beijing Institute, Beijing, China; 4Cancer Bio-
Immunotherapy Center, Fujian Medical University Cancer Hospital & Fujian Cancer
Hospital, Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou,
China; 5Fujian Provincial Key Laboratory of Translational Cancer Medicine, Depart-
ment of Pathology, Fujian Medical University Cancer Hospital & Fujian Cancer Hos-
pital, Fuzhou, China; 6Department of Radiation Oncology, Ruijin Hospital, Shanghai
Jiao Tong University School of Medicine, Shanghai, China; 7Shanghai Lung Cancer
Center, Shanghai Jiao Tong University Affiliated Chest Hospital, Shanghai, China; 8First
Affiliated Hospital, Guangzhou Medical University, Guangzhou, China; 9Department of
Oncology, Affiliated Quanzhou First Hospital of Fujian Medical University, Quanzhou,
China; 10Department of Thoracic Oncology, Peking University Cancer Hospital &
Institute, Beijing, China; 11Department of Internal Medicine, The Affiliated Cancer
Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China;
12
Department of Oncology, The Cancer Hospital of Guangxi Zhuang Autonomous
Region, Nanning, China; 13Department of Radiation Oncology, Fujian Medical Uni-
versity Cancer Hospital & Fujian Cancer Hospital, Cancer Bio-Immunotherapy Center,
Fujian Medical University Cancer Hospital & Fujian Cancer Hospital, Fuzhou, China
Background: In the past decade immune-checkpoint inhibitors (ICIs) has revolution-
ized the treatment of patients with multiple types of cancer, but the predictive
biomarkers are limited. SETD2 is an essential gene related to DNA damage repair
(DDR) and an IFN-a induced immune response, indicating a predictive role in
immunotherapeutic efficacy.
Methods: In our discovery cohort, we reviewed 6726 sequencing samples, among
them 375 samples were detected with SETD2 mutation and 13 patients from 9
centers were ICIs treated. Validation cohort datas included the TCGA, the MSKCC and
the POPLAR/OAK cohort and 10 public ICIs treated cohorts. PolyPhen-2 and SIFT were
used to distinguish deleterious mutations from tolerated mutations. Comparisons of
S390
abstracts
tumor mutation burden (TMB), MSIsensor, survival, immune gene expression were
calculated.
Results: Our discovery cohort showed a high ORR for patients with SETD2 mutation
which was 53.8% (7/13) for all patients with immunotherapy and 42.9% (3/7) for PD-
1/PD-L1 monotherapy. The favored ICIs outcomes was validated by MSKCC-IO cohort
(p<0.0001). A significantly higher TMB was found in SETD2 deleterious mutation
group in our discovery cohort including colorectal cancer (p<0.0001), non-small cell
lung cancer (p<0.0001), melanoma (p¼0.0022) and glioma (p¼0.0042). And the
elevation of TMB and the favored ICIs outcomes were comparable to other molecular
features including POLE/D1, MMRS genes deleterious mutation group. A significantly
higher MSIsensor was found in SETD2 deleterious mutation group in three cancers
with the highest frequency of mismatch repair protein deletions including gastric
adenocarcinoma (p¼0.0029), endometrial carcinoma (p<0.0001), and colorectal
carcinoma (p¼0.0006) and SETD2 was an independent factor influencing MSI-H in
gastric adenocarcinoma (p¼0.003) and colorectal carcinoma (p<0.0001). Tran-
scriptomic analysis in seven solid tumors from the TCGA database showed features of
inflammated tumor microenvironment in tumors with SETD2 deleterious mutation
group especially in renal cell carcinoma, colorectal adenocarcinoma and endometrial
carcinoma.
Conclusions: We identified a new tissue agnosticpredictive biomarker for ICIs: SETD2
deleterious mutation.
Legal entity responsible for the study: The authors.
Funding: Has not received any funding.
Disclosure: All authors have declared no conflicts of interest.
https://doi.org/10.1016/j.annonc.2021.08.359
80P Blood tumor mutational burden (bTMB) and efficacy of
immune checkpoint inhibitors (ICIs) in advanced solid
tumors: SCRUM-Japan MONSTAR-SCREEN
M. Saori1, Y. Nakamura1, K. Sawada2, S. Horasawa3, S. Kadowaki4, K. Kato5,
M. Ueno6, E. Oki7, T. Satoh8, Y. Komatsu9, H. Tukachinsky10, J. Lee10, R. Madison10,
E. Sokol10, D. Pavlick10, A. Aiyer10, D. Fabrizio10, J. Venstrom10, G. Oxnard10,
T. Yoshino1
1
Gastrointestinal Oncology Dept., National Cancer Center Hospital East, Kashiwa,
Japan; 2Department of Medical Oncology, Kushiro Rosai Hospital, Kushiro, Japan;
3
Translational Research Support Section, National Cancer Center Hospital East,
Kashiwa, Japan; 4Clinical Oncology Dept., Aichi Cancer Center Hospital, Nagoya,
Japan; 5Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo,
Japan; 6Department of Gastroenterology, Hepatobiliary and Pancreatic Medical
Oncology Division, Kanagawa Cancer Center, Kanagawa, Japan; 7Department of
Surgery and Science, Kyushu University - Graduate School of Medical Sciences - Faculty
of Medical Sciences, Fukuoka, Japan; 8Department of Frontier Science for Cancer and
Chemotherapy, Osaka University, Osaka, Japan; 9Cancer Center Dept., Hokkaido Uni-
versity Hospital, Sapporo, Japan; 10Foundation Medicine, Cambridge, MA, USA
Background: Association between bTMB and efficacy of ICIs in advanced solid tumors
has not been fully established.
Methods: We collected pretreatment tissue and plasma samples from patients with
advanced solid tumors in SCRUM-Japan MONSTAR-SCREEN, a cancer genomic
screening consortium in Japan, to enable comprehensive genomic profiling (CGP).
Tissue CGP was performed with FoundationOneÒCDx; plasma CGP included Foun-
dationOneÒLiquid plus a 1.125Mb bTMB assay. Mutational burden was calculated by
counting somatic variants (single nucleotide and indels, including synonymous vari-
ants, excluding germline and driver mutations) with a qualifying variant allele fre-
quency. The efficacy of anti-PD-1/PD-L1 with or without anti-CTLA4 therapy according
to TMB value was evaluated by RECIST v1.1.
Results: bTMB results were available in 426 patients enrolled in MONSTAR-SCREEN as
of March 2021; the highest proportion of cancer types were colorectal (23%), fol-
lowed by breast (13%) and pancreatic cancers (11%). Overall, bTMB-high (bTMB-H;
bTMB14 muts/Mb) was detected in 21 patients (4.9%). MSI-H co-occurred in 43%
(9/21) of bTMB-H tumors. Among 329 patients with both tissue and plasma CGP
results (median interval sample collections, 40 days [range 0e5280 days]), a positive
correlation between tissue TMB (tTMB) and bTMB was shown, especially in patients
(N¼109) with an interval between tissue and plasma collections less than 90 days and
composite tumor fraction (cTF)10％ (r¼0.76). In patients who received ICIs
(N¼195), the objective response rate (ORR) was 40% (2/5), 43% (6/14), and 20% (1/5)
in MSI-H, bTMB-H, and tTMB-H patients, respectively. ORR trended higher in bTMB-H
than in bTMB-low patients (43% vs. 19%; p¼0.05).
Conclusions: Elevated bTMB occurred in approximately 5% of patients with advanced
solid tumors. There was positive correlation between bTMB and tTMB in samples
collected at a short interval and cTF10%. The ORR tended to be higher in bTMB-H
patients than in bTMB-low patients, suggesting that bTMB may serve as the potential
biomarker for predicting the efficacy of ICIs. Prospective investigation is warranted to
clarify clinical utility of bTMB for identifying high TMB tumors that may benefit from
ICIs.
Volume 32 - Issue S5 - 2021
abstracts
Legal entity responsible for the study: The authors.
Funding: SCRUM-Japan.
Disclosure: Y. Nakamura: Financial Interests, Institutional, Research Grant: Genomedia; Financial
Interests, Institutional, Research Grant: Guardant Health; Financial Interests, Institutional, Research
Grant: Daiichi Sankyo; Financial Interests, Institutional, Research Grant: Taiho; Financial Interests,
Institutional, Research Grant: Chugai. S. Kadowaki: Financial Interests, Personal, Speaker’s Bureau:
Lilly; Financial Interests, Personal, Speaker’s Bureau: Chugai Pharma; Financial Interests, Personal,
Speaker’s Bureau: Bristol Myers Squibb; Financial Interests, Personal, Speaker’s Bureau: Eisai;
Financial Interests, Personal, Speaker’s Bureau: Merck KGaA; Financial Interests, Personal, Speaker’s
Bureau: Bayer; Financial Interests, Personal, Speaker’s Bureau: Daiichi Sankyo; Financial Interests,
Personal, Speaker’s Bureau: Ono Pharmaceutical; Financial Interests, Personal, Advisory Board:
Daiichi Sankyo; Financial Interests, Institutional, Research Grant: Lilly; Financial Interests, Institu-
tional, Research Grant: Taiho Pharmaceutical; Financial Interests, Institutional, Research Grant: Ono
Pharmaceutical; Financial Interests, Institutional, Research Grant: MSD; Financial Interests, Institu-
tional, Research Grant: Chugai Pharma; Financial Interests, Institutional, Research Grant: Nobel-
pharma. K. Kato: Financial Interests, Institutional, Research Grant: Ono; Financial Interests,
Institutional, Research Grant: MSD; Financial Interests, Institutional, Research Grant: BMS; Financial
Interests, Institutional, Research Grant: Eisai; Financial Interests, Institutional, Research Grant:
Takeda; Financial Interests, Institutional, Research Grant: Astellas; Financial Interests, Institutional,
Research Grant: Bayer; Financial Interests, Personal, Advisory Board: Ono; Financial Interests, Per-
sonal, Advisory Board: BMS; Financial Interests, Personal, Advisory Board: BeiGene; Financial In-
terests, Personal, Advisory Board: MSD; Financial Interests, Personal, Speaker’s Bureau: Eli Lilly;
Financial Interests, Personal, Speaker’s Bureau: Ono; Financial Interests, Personal, Speaker’s Bureau:
BMS; Financial Interests, Personal, Advisory Role: Daiichi Sankyo; Financial Interests, Personal,
Advisory Role: Ono. M. Ueno: Financial Interests, Personal, Invited Speaker: Taiho; Financial In-
terests, Personal, Invited Speaker: Yakult Honsha; Financial Interests, Personal, Invited Speaker:
AstraZeneca; Financial Interests, Personal, Invited Speaker: Merck Biopharma; Financial Interests,
Personal, Invited Speaker: Eisai; Financial Interests, Personal, Invited Speaker: MSD; Financial In-
terests, Personal, Invited Speaker: Servier; Financial Interests, Institutional, Research Grant: Astellas
Pharma; Financial Interests, Institutional, Research Grant: Taiho; Financial Interests, Institutional,
Research Grant: Eisai; Financial Interests, Institutional, Research Grant: AstraZeneca; Financial In-
terests, Institutional, Research Grant: Ono Pharmaceutical; Financial Interests, Institutional, Research
Grant: MSD; Financial Interests, Institutional, Research Grant: Merck Biopharma; Financial Interests,
Institutional, Research Grant: Incyte; Financial Interests, Personal, Invited Speaker: Chugai; Financial
Interests, Institutional, Research Grant: Chugai. E. Oki: Financial Interests, Personal, Invited Speaker:
Taiho Pharmaceutical Co. Ltd.; Financial Interests, Personal, Invited Speaker: Ono Pharmaceutical Co.
Ltd.; Financial Interests, Personal, Invited Speaker: Chugai Pharmaceutical Co. Ltd.; Financial In-
terests, Personal, Invited Speaker: Bayer; Financial Interests, Personal, Invited Speaker: Eli Lilly;
Financial Interests, Personal, Invited Speaker: Bristol Myers Squibb; Financial Interests, Personal,
Invited Speaker: Takeda Pharmaceutical Co. Ltd. T. Satoh: Financial Interests, Personal and Institu-
tional, Research Grant: Ono pharmaceutical; Financial Interests, Personal and Institutional, Research
Grant: Chugai Pharmaceutical; Financial Interests, Personal and Institutional, Research Grant: Yakult
Honsha; Financial Interests, Institutional, Research Grant: Giliad; Financial Interests, Institutional,
Research Grant: Bristol-Myers; Financial Interests, Institutional, Research Grant: MSD; Financial In-
terests, Institutional, Research Grant: Daiichi Sankyo; Financial Interests, Personal and Institutional,
Research Grant: Eli Lilly; Financial Interests, Personal, Invited Speaker: Ono Pharmaceutical; Financial
Interests, Personal, Invited Speaker: Chugai Pharmaceutical; Financial Interests, Personal, Invited
Speaker: Yakult Honsha; Financial Interests, Personal, Invited Speaker: Bristol-Myers; Financial In-
terests, Personal, Invited Speaker: Daiichi Sankyo; Financial Interests, Personal, Invited Speaker: Eli
Lilly; Financial Interests, Personal and Institutional, Research Grant: BeiGene. Y. Komatsu: Financial
Interests, Personal, Research Grant: Ono Pharmaceutical Co., Ltd.; Financial Interests, Personal,
Research Grant: TAIHO Phamaceutical Co., Ltd; Financial Interests, Personal, Research Grant: Chugai
Pharmaceutical Co., Ltd.; Financial Interests, Personal, Research Grant: Eli Lilly and Company;
Financial Interests, Personal, Research Grant: Mediscience Planning Inc.; Financial Interests, Per-
sonal, Research Grant: NanoCarrier Co.,Ltd; Financial Interests, Personal, Research Grant: Yakult;
Financial Interests, Personal, Research Grant: Daiichi Sankyo Company, Limited; Financial Interests,
Personal, Research Grant: IQVIA Services Japan K.K; Financial Interests, Personal, Research Grant:
Japanese Foundation for Multidisciplinary Treatment of Cancer; Financial Interests, Personal,
Research Grant: Nationel Cancer Center Japan; Financial Interests, Personal, Speaker’s Bureau:
Chugai Pharmaceutical Co., Ltd.; Financial Interests, Personal, Speaker’s Bureau: Bayer Yakuhin, Ltd.;
Financial Interests, Personal, Speaker’s Bureau: Eli Lilly and Company; Financial Interests, Personal,
Speaker’s Bureau: Ono Pharmaceutical Co., Ltd.; Financial Interests, Personal, Speaker’s Bureau:
TAIHO Phamaceutical Co., Ltd. H. Tukachinsky: Financial Interests, Personal, Full or part-time
Employment: Foundation Medicine, Inc; Financial Interests, Personal, Stocks/Shares: Roche. J. Lee:
Financial Interests, Personal, Full or part-time Employment: Foundation Medicine; Financial In-
terests, Personal, Stocks/Shares: Roche. R. Madison: Financial Interests, Personal, Full or part-time
Employment: Foundation Medicine; Financial Interests, Personal, Stocks/Shares: F. Hoffmann-La
Roche AG. E. Sokol: Financial Interests, Personal, Full or part-time Employment: Foundation Medi-
cine; Financial Interests, Personal, Stocks/Shares: Roche. D. Pavlick: Financial Interests, Personal, Full
or part-time Employment: Foundation Medicine; Financial Interests, Personal, Stocks/Shares: F.
Hoffmann-La Roche AG. A. Aiyer: Financial Interests, Personal, Full or part-time Employment:
Foundation Medicine; Financial Interests, Personal, Stocks/Shares: Roche. D. Fabrizio: Financial In-
terests, Personal, Full or part-time Employment: Foundation Medicine; Financial Interests, Personal,
Stocks/Shares: Roche. J. Venstrom: Financial Interests, Personal, Full or part-time Employment:
Foundation Medicine; Financial Interests, Personal, Stocks/Shares: Roche. G. Oxnard: Financial In-
terests, Personal, Full or part-time Employment: Foundation Medicine; Financial Interests, Personal,
Stocks/Shares: Roche. T. Yoshino: Financial Interests, Personal, Invited Speaker: Taiho; Financial In-
terests, Personal, Invited Speaker: Chugai; Financial Interests, Personal, Invited Speaker: Eli Lilly;
Financial Interests, Personal, Invited Speaker: Merck Biopharma; Financial Interests, Personal, Invited
Speaker: Bayer; Financial Interests, Personal, Invited Speaker: Ono; Financial Interests, Institutional,
Research Grant: Taiho; Financial Interests, Institutional, Research Grant: Sumitomo Dainippon;
Financial Interests, Institutional, Research Grant: Ono; Financial Interests, Institutional, Research
Grant: Chigai; Financial Interests, Institutional, Research Grant: Amgen; Financial Interests, Institu-
tional, Research Grant: Parexel International; Financial Interests, Institutional, Research Grant: MSD;
Financial Interests, Institutional, Research Grant: Daiichi Sankyo; Financial Interests, Institutional,
Research Grant: Sanofi. All other authors have declared no conflicts of interest.
https://doi.org/10.1016/j.annonc.2021.08.360
Volume 32 - Issue S5 - 2021
Annals of Oncology
81P Baseline circulating CD4+PD1+high T cells (TCD4PD1H) as
predictors of survival in patients (P) with solid tumors
treated with immune-checkpoint inhibitors (ICI)
J. Garcia-Corbacho1, A.E. González Navarro2, I. Victoria1, D. Moreno1, L. Heredia2,
I. Ortiz de Landázuri1, V. Díez-Guardia3, E. Sanfeliu4, A. Indacochea1, L. Angelats1,
N. Viñolas1, B. Mellado5, T. Saurí1, J. Maurel5, L. Mezquita1, E. Pineda6, N. Basté1,
A. Prat5, M. Juan2, F. Schettini3
1
Oncology and Hematology Department, Hospital Clinic y Provincial de Barcelona,
Barcelona, Spain; 2Immunology Department, Hospital Clinic y Provincial de Barcelona,
Barcelona, Spain; 3Translational Genomics and Targeted Therapies in Solid Tumors,
IDIBAPS - August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain;
4
Department of Pathology, Hospital Clinic of Barcelona, Barcelona, Spain; 5Medical
Oncology Department, Hospital Clinic y Provincial de Barcelona, Barcelona, Spain;
6
Medical Oncology, Hospital Clínic de Barcelona, Barcelona, Spain
Background: PD1 is an inhibitory receptor exposed on the surface of T cells and other
immune cells. In non-small cell lung cancer and melanoma P, as well as after stem cell
transplantation, higher levels of CD4+ T cells (TCD4) expressing PD1 (PD1+) correlated
with poor survival outcomes. Nonetheless, in vitro PD1 blockade enhanced antitumor
immunity. Finally, subpopulations of TCD4 with higher or lower PD1+ levels were
identified and associated with differential functional effects and prognosis in follicular
lymphoma. We thus aimed at elucidating the prognostic role of peripheral TCD4PD1+
and TCD4PD1H in cancer P treated with ICI-based regimens.
Methods: From 69 consecutive P with solid tumors treated with ICI, we prospectively
collected baseline blood samples and evaluated with flow cytometry the proportion
(%) of TCD4PD1+ and TCD4PD1H. We performed univariate Cox regressions to detect
an association with progression-free survival (PFS) and overall survival (OS). A
maximally selected rank statistic method was applied to define a cut-off to identify
patients with low and high levels of the specific T cell subpopulation of interest. An
association with PFS, OS, and overall response rates (ORR) was then explored ac-
cording to subgroups. Significance was set at p<0.05.
Results: Median proportion of TCD4PD1+ was 13.9% (interquartile range [IQR]: 9.3e
17.4%) and of TCD4PD1H was 0.7% (IQR: 0.3-1.3%). A significant association of
TCD4PD1H% levels with OS was observed (hazard ratio [HR]:1.15, p¼0.048). A cut-off
of 1.1% defined 2 prognostically significant subgroups of P (above and below the
threshold, 19 vs. 50 P, respectively). TCD4PD1HBelow vs. TCD4PD1HAbove presented
with better PFS (adjusted HR [aHR]: 0.52, 95% confidence intervals [CI]: 0.28 e 0.98,
p¼0.041), OS (aHR: 0.39, 95%CI: 0.21 - 0.72, p¼0.003) and ORR (20.0% vs 0.0%, c2
p¼0.035).
Conclusions: Low levels of TCD4PD1H in solid tumors before starting ICI seem to
correlate with better ORR, PFS and OS, independently from cancer type, metastatic
patterns, P and treatment characteristics. The recruitment of a validation cohort is
ongoing, as well as a sub-analysis focused on anti-PD1/antiPDL1.
Legal entity responsible for the study: The authors.
Funding: Has not received any funding.
Disclosure: J. Garcia-Corbacho: Financial Interests, Personal, Advisory Role: Johnson and Johnson
Pharmaceutical; Financial Interests, Personal, Project Lead, Local PI: Amgen, Astellas, AstraZeneca,
Bayer, Boehringer, Cytomx, Daichii Sankyo, Incyte, Lilly, Menarini, Merck. L. Mezquita: Financial In-
terests, Personal, Advisory Role: Roche, Roche Diagnostics, Takeda; Financial Interests, Personal,
Invited Speaker: Roche, Bristol Myers Squibb, Tecnofarma; Financial Interests, Personal, Other,
travel/accomodation expenses: Roche, Bristol Myers Squibb. A. Prat: Financial Interests, Personal,
Advisory Role: Novartis, Roche, AstraZeneca, BMS, Daiichi Sankyo, Guardant Health, Oncolytics
Biotech, Foundation Medicine and Nanostring Technologies. All other authors have declared no
conflicts of interest.
https://doi.org/10.1016/j.annonc.2021.08.361
82P HLA-I heterozygosity and increased incidence of immune
related toxicity among non-small cell lung cancer (NSCLC)
patients treated with single agent immunotherapy
N.C. Law1, E.S. Gray2, A. Abed2
1
Medical Oncology, Fiona Stanley Hospital, Perth, WA, Australia; 2School of Medical
and Health Sciences, Edith Cowan University, Joondalup, WA, Australia
Background: Immune-mediated adverse events (IRAE) can result in treatment
cessation and has a negative impact on immunotherapy efficacy among NSCLC pa-
tients treated with single agent immunotherapy. Predicting those who are more likely
to experience IRAE may help identify those at risk in order to reduce morbidity and
mortality associated with it. While strong associations between human leucocyte
antigen (HLA) and autoimmune disease is well documented, the association between
HLA and IRAE among NSCLC is still unclear.
S391